Skip to main content

NanoView, Beth Israel Deaconess Medical Center Launch Immuno-Oncology Biomarker Study

NEW YORK – NanoView Biosciences said on Thursday that it has signed an agreement with Beth Israel Deaconess Medical Center to study biomarkers carried by exosomes in patients undergoing immune checkpoint inhibitor therapy (ICIT) for cancer.

As part of the "ExoPDL-1 to Predict Immunotherapy Response in Cancer" (EPIC) study, the team will use Boston-based NanoView's ExoView platform to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing ICIT.

The research-use-only ExoView platform is an antibody labeling and imaging-based tool that offers high-resolution sizing, counting, and phenotyping of extracellular vesicles and viral vectors.

Bruno Bockorny, an oncologist from BIDMC, will serve as the study's principal investigator. Co-investigators will include Vassiliki Boussiotis, professor at BIDMC, and Daniel Costa, associate professor at Harvard Medical School.

"Our current ability to predict which patients are most likely to benefit from immunotherapy is very limited," Boussiotis said in a statement. "Even for cancer types with significant level of PD-L1 expression … there is [frequently] discordance between PD-L1 expression level and response to treatment."

Financial details of the agreement were not disclosed.

"We are pleased that BIDMC will help evaluate data from our ExoView platform to better understand the role that exosome-associated biomarkers play in disease status and therapeutic response for cancer patients," Jerry Williamson, CEO of NanoView, said in a statement.

NanoView previously signed an exclusive agreement with Quantum Design to distribute the ExoView platform in China.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.